Provided By GlobeNewswire
Last update: May 1, 2025
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant (“CA”) use is associated with better management of congestive heart failure (“CHF”). The analysis, titled “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care,” details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PCP that uses Counterpart Assistant.
Read more at globenewswire.comNASDAQ:CLOV (6/6/2025, 1:47:08 PM)
3.045
+0.02 (+0.83%)
Find more stocks in the Stock Screener